20 hrs ago
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in ...
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Fri Mar 07, 2014
Sunitinib in combination with trastuzumab for the treatment of...
This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer .
Thu Mar 06, 2014
Fri Feb 28, 2014
Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual...
The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
Wed Feb 26, 2014
Epigenetic silencing of miR-375 induces trastuzumab resistance in...
Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab , has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers.
Genentech's Distribution of Prescribing Information to...
On January 31, 2014, Phigenix, Inc. filed a lawsuit in federal district court in Georgia alleging that the sale and use of the drug Kadcyla by Genentech, Inc. infringed U.S. Patent No.
Thu Feb 20, 2014
Applied Clinical Trials
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial ...
ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Tue Feb 18, 2014
Natural compound attacks HER2 positive breast cancer cells
A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.
Thu Feb 13, 2014
Wed Feb 12, 2014
Breast Cancer Vaccine Shows Promise in Mid-Stage Trial
Promising results have been reported from a phase II study of an investigational cancer vaccine designed to prevent relapse in patients who have had breast cancer.